Pharmaceutical combination for treatment of bone-wasting diseases
US5071655A · kind A · utility
4Cited by
4References
18Claims
0Family size
Inventor
Key dates
| Filing date | Jan 12, 1990 |
| Grant date | Dec 10, 1991 |
| Priority date | — |
| Expiry date | Jan 12, 2010 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61L2430/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A pharmaceutical composition for increasing bone mass and preventing loss of bone mass is provided, comprising a fluoride source and a mitogenic hydantoin in combination with a pharmaceutically acceptable carrier, in which the fluoride source provides a molar ratio of fluoride ion to hydantoin in the composition of from about 0.1:1 to about 100:1. The combination is administered to a vertebrate, typically in the form of an orally administratable tablet or capsule.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.